Bone Marrow. Plasma Cells. Monoclonal Gammopathy of Undetermined Significance.
- The Christians Handbook of Biblical Scholarship?
- Reaching the Lost (Sword of the Spirit Book 8).
- VTLS Chameleon iPortal Browse Results!
- Serenity House Trilogy?
Angiogenesis Inducing Agents. Bone Marrow Cells. Endothelial Cells.
Strategies for the Treatment of Multiple Myeloma in 2013: Moving Toward the Cure
Stromal Cells. Mast Cells. Cell Movement. Cell Survival.
Bentham Science Publishers Ltd.. Bentham Science Publishers Ltd. Ribatti D, Vacca A. Ribatti, Domenico ; Vacca, Angelo.
Access to Document Dhakal B, et al. JAMA Oncol.
Saad Z. Usmani Treatment with high-dose melphalan followed by autologous hematopoietic stem cell transplant conferred longer PFS with minimal toxic effects compared with novel agents among patients with multiple myeloma , according to results from a meta-analysis published in JAMA Oncology. None of these approaches had a significant effect on OS. Study limitations included a limited number of studies, heterogeneous treatments delivered and unreported outcomes. Autologous HSCT has been the standard of care for younger patients with multiple myeloma for decades.
Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins.
With the introduction of novel agents, the role of autologous HSCT has been repeatedly challenged, partly due to the perceived high costs and the potential morbidity and mortality associated with the transplant. Many transplants occurred in outpatient units. In this meta-analysis, the authors have demonstrated that, despite the use of novel agents for induction, transplant continues to improve PFS, but not OS, compared with a nontransplant approach.
Thus, this meta-analysis strongly supports the continued role of autologous HSCT as part of the initial treatment for patients with multiple myeloma.
Related Multiple Myeloma - A New Era of Treatment Strategies
Copyright 2019 - All Right Reserved